TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > TGA continues to lead the way in Prescription Medicine Transparency

TGA continues to lead the way in Prescription Medicine Transparency

Author: Reena Patel

Several years ago, the Australian Therapeutic Goods Administration (TGA) embarked on a journey to increase the transparency of the Australian prescription medicine evaluation process as part of the Business Process Reforms Initiative.

This commenced with the publication of Australian Public Assessment Reports (AusPARs) in November 2009. Each publicly available report provides an overview of the scientific reasoning upon which the TGA’s decision to approve or refuse a prescription medicine application was made. Although the TGA’s AusPARs were modelled on the European Public Assessment Reports (EPARs), unlike their European counterparts the TGA’s preferred approach was to publish an AusPARs per evaluation instead of medicine. Additionally, Australian assessment reports were only published for major applications where advice from the Advisory Committee for Medicines had been sought as part of the regulatory review. Consistent with the principles of continuous improvement the TGA have refined the content of the AusPAR over time, and a streamlined version of the document was implemented in September 2019.The latest reiteration now simply includes an introduction, registration timeline, Delegates action and Advisory Committee resolution. The resulting assessment report is a substantially smaller document than that published at inception, and as a result is now typically available in much closer proximity to the regulatory decision than in previous years.

Whilst not all new prescription medicine evaluations result in the publication of an AusPAR, the TGA did embark on another transparency initiative for new prescription medicine decisions effective 1 September 2019. The publication of an Australian Prescription Medicine Decision Summary was intended to provide information in a more consumer friendly format and is available for new chemical or biological medicine registrations. The TGA aims to publish this summary within 10 days of inclusion of the new medicine on the Australian Register to Therapeutic Goods (ARTG).

The TGA also routinely publishes abbreviated information on new prescription medicines and biologicals as they are approved. This includes new medicines, extended uses (‘extensions of indications’) or new combinations of already registered medicines, and new generic or biosimilar medicines. Typically, this will include tradename/active ingredient, sponsor, indications, type of application and registration timeline (as applicable).

Collectively these measures demonstrate the TGA’s continued commitment to transparency as it relates to prescription medicine evaluation. It is however acknowledged that the focus to-date has been on publication of information at the end of the evaluation process, and as yet there is much less visibility as to prescription medicine applications which are under review. Disclosure of applications which are actually under evaluation is considered to be a much more commercially sensitive matter and in addressing this, requires the management of competing needs of different stakeholders.

In February 2019, the TGA sought comments from interested parties on whether the TGA should publish that a prescription medicine is under evaluation. The impetus for the consultation was multi-factorial and included increasing demands from the general public for knowledge of marketing applications, an awareness that due to parallel review processes and shared evaluations, information is often available in the public domain (eg. scheduling, reimbursement applications, overseas regulators) whilst acknowledging the potential commercial sensitivity of its release.

The consultation proposed four options for stakeholders:

  1. Maintain the status quo ie. no publication of information for new medicines under review.
  2. Publication of information for all new medicines at the same time (acceptance into evaluation), this would apply for new chemical entities (including biological prescription medicines), extensions of indications, all generic and biosimilar medicines.
  3. Publication of all applications at two different time points depending on whether the medicine is a new medicine or a generic medicine or biosimilar.
  4. Publication of applications for innovator medicines of highest public interest, but not generic or biosimilar medicines.

Thirty-nine submissions were received from industry, health professionals, consumer representative groups, regulatory consultants and government. Companies with novel medicines tended to strongly advocate for an equitable approach to transparency, supporting Option 2, which proposed the publication of all new medicines at the same time. In contrast suppliers of generic medicines noted that the disclosure of information for generics and biosimilars would be commercially disadvantageous, and preferred retention of the current model.

On 8 April 2020, the TGA announced that the Australian Government had given approval to proceed with implementation of enhanced transparency measures for prescription medicines, and advised an intention to implement the following measures:

  • Early publication of major innovator medicine applications
    Introduce earlier publication of major innovator prescription medicines that have been accepted for evaluation under section 25 of the Act. The measure will provide information on potential availability of new medicines, or new uses for medicines and new combinations (where one active ingredient is a new medicine). Publication will occur from June 2020.
  • Earlier notification of generic medicine applications to the innovator
    This measure will introduce earlier notification of generic medicine applications to the innovator. Implementation is planned for early 2021.

In relation to the generic application notification, a second round of consultation (which concludes on 9 June 2020) has been initiated that outlines TGA’s attempts to navigate a pathway between balancing the need for public disclosure and commercial sensitivity. In particular, the TGA is now seeking feedback on two options for implementing an early notification scheme for new generic medicines, specifically:

  • Option 1 – Early notification only where a patent has not expired Where an applicant has a reasonable belief that a patent has not expired, it would be required to provide a confidential notification to the patentee that the application has passed preliminary assessment. The purpose of this option is to remove the assessment of whether the marketing of the generic would infringe a valid claim of a patent from being at the sole discretion of the applicant.
  • Option 2 – Early notification regardless of belief of the existence of a patent
    This option would apply to all applicants where it is proposed that the application rely on information of another to support that application. All applicants would be required to provide a notification to the innovator, and a copy of the notification to TGA. This option, in addition to moving the current certification or notification requirements to the earlier point in the process also require the applicant to provide notification to the innovator where the applicant determines that a valid patent is not infringed.

Whilst the TGA’s framework for increasing transparency continues to evolve, the current consultation demonstrates the TGA’s commitment in pursuing a balanced approach to transparency.

Links and Resources

Access Australian Public Assessment Reports (AusPARs), Australian Prescription Medicine Decision Summaries or Prescription Medicine New Registrations here.

TGA Consultation on Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator applications here.

Contact us
Related posts
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
26th February 2022
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
24th February 2022
Recent Blogs
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
  • How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
    26th February 2022
  • Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
    24th February 2022
Recent News
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
  • PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
    8th February 2022
  • Virtual Audits: To be, or not to be, that is the question
    26th January 2022
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
6h

At PharmaLex, one of our core values is expanding our global community. In March, we welcomed Japan, East Asia, and Southeast Asia into our global pharmaceutical #productdevelopment as a result of a merger agreement with Ascent Development Services.
https://lnkd.in/eGFf_AKv

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.

    Top 10 Pharma Company
    President
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for